• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Boehringer-Ingelheim Satellite Symposium Choosing the Right Controller Therapy in Pediatric Patients with Asthma.

作者信息

Szefler Stanley J

机构信息

The Breathing Institute and Pulmonary Medicine Section, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado.

出版信息

Pediatr Pulmonol. 2018 Jun;53(S1):S171-S173. doi: 10.1002/ppul.24035.

DOI:10.1002/ppul.24035
PMID:29906344
Abstract
摘要

相似文献

1
Boehringer-Ingelheim Satellite Symposium Choosing the Right Controller Therapy in Pediatric Patients with Asthma.勃林格殷格翰卫星研讨会：为儿童哮喘患者选择合适的控制疗法
Pediatr Pulmonol. 2018 Jun;53(S1):S171-S173. doi: 10.1002/ppul.24035.
2
Tipranavir: PNU 140690, tipranivir.替拉那韦：PNU 140690，替拉那韦。
Drugs R D. 2006;7(1):55-62. doi: 10.2165/00126839-200607010-00005.
3
Abstracts: VI Scandinavian COPD Research Symposium Published with support from Boehringer Ingelheim.摘要：第六届斯堪的纳维亚慢性阻塞性肺疾病研究研讨会 由勃林格殷格翰公司支持出版。
Eur Clin Respir J. 2015 Nov 5;2(Suppl 1):30020. doi: 10.3402/ecrj.v2.30020. eCollection 2015.
4
Asthma Severity in patients initiating controller monotherapy versus combination therapy.起始控制单一疗法与联合疗法患者的哮喘严重程度
J Asthma. 2011 Apr;48(3):304-10. doi: 10.3109/02770903.2011.555034. Epub 2011 Feb 28.
5
Treatment of ventricular arrhythmias: role of mexiletine: symposium held under the patronage of the Belgian Society of Cardiology and organized by Boehringer Ingelheim.
Acta Cardiol Suppl. 1980(25):1-185.
6
[Long-term oxygen therapy--from whom and how? Results of expert discussion in the framework of Pneumology Workships "COPD--an inventory at the beginning of the 21st century by Boehringer Ingelheim Pharma KG, Ingelheim on January 21 2000 in Seefeld, Tyrol].
Pneumologie. 2000 Jul;54(7):309-11. doi: 10.1055/s-2000-4458.
7
Total Synthesis of Apoptolidin: Part 1. Retrosynthetic Analysis and Construction of Building Blocks We thank Dr. D. H. Huang and Dr. G. Siuzdak for NMR spectroscopic and mass spectrometric assistance, respectively. This work was financially supported by the National Institutes of Health (USA), the Skaggs Institute for Chemical Biology, American Biosciences, a pre-doctoral fellowship from Boehringer Ingelheim (Y.L.), a postdoctoral fellowship the George Hewitt Foundation (K.C.F.), and grants from Abbott Laboratories, ArrayBiopharma, Bayer, Boehringer Ingelheim, DuPont, Glaxo, Hoffmann-LaRoche, Merck, Novartis, Pfizer, and Schering Plough.凋亡诱导素的全合成：第1部分。逆合成分析与构建模块 我们分别感谢D. H. Huang博士和G. Siuzdak博士在核磁共振光谱和质谱分析方面提供的帮助。这项工作得到了美国国立卫生研究院、斯卡格斯化学生物学研究所、美国生物科学公司的资助，勃林格殷格翰公司提供的博士前奖学金（Y.L.）、乔治·休伊特基金会提供的博士后奖学金（K.C.F.），以及雅培实验室、Array生物制药公司、拜耳公司、勃林格殷格翰公司、杜邦公司、葛兰素公司、霍夫曼 - 罗氏公司、默克公司、诺华公司、辉瑞公司和先灵葆雅公司的资助。
Angew Chem Int Ed Engl. 2001 Oct 15;40(20):3849-3854.
8
Total Synthesis of Apoptolidin: Part 2. Coupling of Key Building Blocks and Completion of the Synthesis We thank Dr. C. Khosla and Dr. Y. Hayakawa for generous gifts of apoptolidin, and Dr. D. H. Huang and Dr. G. Siuzdak for NMR spectroscopic and mass spectrometric assistance, respectively. This work was financially supported by the National Institutes of Health (USA), the Skaggs Institute for Chemical Biology, American Biosciences, a predoctoral fellowship from Boehringer Ingelheim (to Y.L.), a postdoctoral fellowship the George Hewitt Foundation (to K.C.F.), and grants from Abbott Laboratories, ArrayBiopharma, Bayer, Boehringer Ingelheim, DuPont, Glaxo, Hoffmann-LaRoche, Merck, Novartis, Pfizer, and Schering Plough.
Angew Chem Int Ed Engl. 2001 Oct 15;40(20):3854-3857.
9
BIII-890-CL. Boehringer Ingelheim.
Curr Opin Investig Drugs. 2002 Dec;3(12):1733-5.
10
Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.噻托溴铵治疗 1-5 岁持续性哮喘症状患儿的安全性和有效性：一项随机、双盲、安慰剂对照试验。
Lancet Respir Med. 2018 Feb;6(2):127-137. doi: 10.1016/S2213-2600(18)30012-2. Epub 2018 Jan 18.

引用本文的文献

1
Addressing the risk domain in the long-term management of pediatric asthma.解决儿童哮喘长期管理中的风险领域。
Pediatr Allergy Immunol. 2020 Apr;31(3):233-242. doi: 10.1111/pai.13175. Epub 2019 Dec 11.
2
Can early intervention in pediatric asthma improve long-term outcomes? A question that needs an answer.儿童哮喘的早期干预能否改善长期预后？这是一个需要回答的问题。
Pediatr Pulmonol. 2019 Mar;54(3):348-357. doi: 10.1002/ppul.24224. Epub 2019 Jan 4.